Amneal Pharmaceuticals, Inc. (2DT.F)

4,6600 -0,0800 (-1,69%) Ab 9:16AM MESZ. Markt geöffnet.

Amneal Pharmaceuticals, Inc.

400 Crossing Boulevard
3rd Floor
Bridgewater, NJ 08807
United States
908 947 3120
http://www.amneal.com

Sektor(en): Healthcare
Branche: Drug Manufacturers—Specialty & Generic
Vollzeitmitarbeiter: 6.000

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Chirag K. Patel	Co-Founder, Co-CEO, Pres & Director	22,04k	N/A	1967
Mr. Chintu Patel R.Ph., R.Ph	Co-Founder, Co-CEO & Director	29,85k	N/A	1972
Mr. Anastasios G. Konidaris	Exec. VP & CFO	856,85k	N/A	1967
Ms. Nikita Shah	Exec. VP and Chief HR Officer & Strategic Planning Officer	720,52k	N/A	1978
Mr. Joseph Todisco MBA	Exec. VP & Chief Commercial Officer of Specialty	790,12k	N/A	1976
Mr. Andrew S. Boyer	Exec. VP & Chief Commercial Officer of Generics	1,15M	N/A	1966
Mr. Stephen J. Manzano	Sr. VP, Gen. Counsel & Corp. Sec.	N/A	N/A	1965
Mr. Sanjiv Patel	Sr. VP of Operations	N/A	N/A	N/A
Dr. Nikunj Patel	Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd	N/A	N/A	N/A
Mr. Sanjay Kumar Jain	Pres of India Operations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2020 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.

Corporate Governance

Amneal Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. April 2021, lautet 6. Die grundlegenden Scores sind Audit: 8, Vorstand: 9, Shareholderrechte: 4, Kompensation: 4.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.